NCT04046016View on ClinicalTrials.gov

A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

December 24, 2018

Study Completion Date

December 24, 2018

Conditions
Solid Tumor
Interventions
DRUG

Paclitaxel

Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).

Trial Locations (1)

Unknown

Seoul National University Bundang Hospital, Seongnam

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04046016 - A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor | Biotech Hunter | Biotech Hunter